User menu

Endocrine Profiles During Administration of the New Nonsteroidal Antiandrogen Casodex in Prostate-cancer

Bibliographic reference Verhelst, J. ; Denis, L. ; Vanvliet, P. ; Vanpoppel, H. ; Braeckman, J. ; et. al. Endocrine Profiles During Administration of the New Nonsteroidal Antiandrogen Casodex in Prostate-cancer. In: Clinical Endocrinology, Vol. 41, no. 4, p. 525-530 (1994)
Permanent URL http://hdl.handle.net/2078.1/48680
  1. Cockshott I.D., European Urology, 18, 10 (1990)
  2. Denis L., Therapeutic Progress in Urological Cancers, 30, 95 (1989)
  3. Denis L., Murphy G. P., Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer, 10.1002/1097-0142(19931215)72:12+<3888::aid-cncr2820721726>3.0.co;2-b
  4. DORFMAN RALPH I., BIOLOGICAL ACTIVITY OF ANTIANDROGENS, 10.1111/j.1365-2133.1970.tb07998.x
  5. Ekman Peter, Oestrogens and Estracyt in Prostate Cancer, The Medical Management of Prostate Cancer II (1991) ISBN:9783642762802 p.45-52, 10.1007/978-3-642-76278-9_5
  6. Freeman SN, Mainwaring WIP, Furr BJA, A possible explanation for the peripheral selectivity of a novel non-steroidal pure antiandrogen, Casodex (ICI 176,334), 10.1038/bjc.1989.336
  7. Furr B.J.A., European Urology, 18, 2 (1990)
  8. Furr B.J.A., Journal of Endrocinology, 113, 3 (1987)
  9. Goldenberg S.L., Urological Clinics of North America, 18, 111 (1991)
  10. Harnois C., Malenfant M., Dupont A., Labrie F., Ocular toxicity of Anandron in patients treated for prostatic cancer., 10.1136/bjo.70.6.471
  11. Hellman L., Journal of Clinical Endocrinology and Metabolism, 45, 1224 (1977)
  12. Iversen P., Proceedings of the 3rd International Symposium on Recent Advances in Urological Cancer. Diagnosis and Treatment, 120 (1992)
  13. Kennealy G.T., Urological Clinics of North America, 10, 99 (1991)
  14. Labrie F., Hormonal Manipulation of Cancer: Peptides, Growth Factors and (anti)-Steroidal Agents, 291 (1986)
  15. Larsen L.G., Acta Radiologica, 58, 253 (1962)
  16. Lund F., British Journal of Urology, 61, 140 (1988)
  17. Mahler C., Denis L., Clinical profile of a new non-steroidal antiandrogen, 10.1016/0960-0760(90)90444-p
  18. Moguilewsky M., Bertagna C., Hucher M., Pharmacological and clinical studies of the antiandrogen Anandron, 10.1016/0022-4731(87)90162-2
  19. Migliari R., Journal of Urology, 148, 338 (1992)
  20. Neri R., Pharmacology and Clinical Uses of Inhibitors of Hormone Secretion and Action, 160 (1987)
  21. Neumann F., Clinical Oncology, 1, 41 (1982)
  22. Neumann F., Pharmacology and Clinical Uses of Inhibitors of Hormone Secretion and Action, 132 (1987)
  23. Newling D.W.W., European Urology, 18, 18 (1990)
  24. Petros J.A., Urological Clinics of North America, 20, 749 (1993)
  25. Weinstein R.L., Journal of Clinical Investigation, 53, 1 (1974)
  26. Zumoff B., Journal of Clinical Endocrinology and Metabolism, 49, 467 (1979)